Pediatric Psoriasis Market: By Type (Plaque Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Inverse Psoriasis, Erythrodermic Psoriasis, Mucosal/oral Psoriasis, Nail Psoriasis, Napkin or Diaper Psoriasis, Photosensitive Psoriasis, and Flexural Psoriasis), By Treatment (Topical therapy, Oral, Injections, Biologics, Natural supplements, and Phototherapy), By End User (Hospitals, Specialty Clinics, Ambulatory Care Centers, and Research Organizations) and Geography  

Pediatric Psoriasis Market size was valued at USD 11,372.8 million in 2022 and is poised to grow at a CAGR of 8.7% from 2023-29. Psoriasis is an autoimmune inflammatory disorder that causes excessive skin cell production, resulting in an itchy, painful skin condition characterized by inflammation, red lesions, and plaque formation. There are mainly two types of psoriasis: plaque psoriasis and psoriatic arthritis (PsA). According to a study published by Celgene Corporation, around 30.0% of patients suffering from the illness develop psoriatic arthritis, which is an inflammation of the joints. The rapidly growing neonatal population born with autoimmune disease, rising prevalence of plaque and psoriatic arthritis, a large pipeline of biologic and biosimilar products, favorable reimbursement policies, and rising biologic product prescription volume are all major factors driving the pediatric psoriasis market growth in the forecast period. According to the National Psoriasis Foundation (NPF), there will be around 125 million psoriasis patients worldwide in 2021. Approximately 14.8% to one-third of all psoriasis cases occur by the age of 15, making this illness a severe global problem. The prevalence of this ailment ranges from 1.5 to 5.0% in most developed countries, with an upward trend linearly from the age of 1-year-old to 18 years old in disease prevalence observed in recent years. The rising incidence of psoriasis around the world has created a significant demand for safe and effective treatment options. Which can be predicted to boost the pediatric psoriasis market size in the prophecy period. For example, according to U.S. Census data, the reported number of cases in the United States in 2021 was roughly 8 million. In addition, MedPage Today, LLC. article published in November 2021 stated that a six-month delay in diagnosing psoriatic arthritis could result in joint erosions, damage, and incapacity. Furthermore, with a thorough analysis of the pediatric psoriasis market insight, it can be estimated that with a recent wave of biologicals in the treatment of psoriatic diseases, FDA approvals of new drugs are predicted to shape the pediatric psoriasis market growth more than expected by the end of 2028, leveraging a considerable market potential for investment in novel product development and clinical trials. Psoriasis is a chronic condition that costs a great deal of money to treat. According to the financial evaluation for psoriasis therapy, medicine expenditures account for around 20.0% of overall costs. According to the NPF, one in every three individuals suffering from the disease has difficulty paying for therapy, and a tube of topical drugs may cost between USD 500 and USD 600. Furthermore, biologics could cost between USD 15,000 and USD 20,000 per year. Thus, despite increased disease prevalence, high medicine prices for treatment and a lack of favorable reimbursement policies in emerging nations are the primary factors limiting market growth over the forecast period.  

Pediatric Psoriasis Market Key Developments:

• FDA approved Novartis Cosentyx for moderate to severe psoriasis in children and adolescents. In April 2020, Eli Lilly’s Ixekizumab was approved for pediatric plaque psoriasis treatments.